ARS Pharmaceuticals (SPRY)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+322.3%

$23.25 average target

$5.50+0.00 (+0.0%)Latest market snapshot · Yahoo Finance

Market cap$547.5M

Cash$143.8M

Quarterly burn$44.9M

Pipeline assets3

Short float31.2%

Clinical portfolio

ARS Pharmaceuticals Drug Pipeline

Showing 1 of 3

Asset	Indication	Stage	Milestone	Signals ?
neffy® (epinephrine nasal spray)	Acute flares in patients with chronic spontaneous urticaria	Phase 2b	Mar 31, 2027	Potential moverMgmt interest

Continue with BioPharma ProUnlock 2 additional programs and complete development details.

Unlock Pro

Upcoming milestones

SPRY Catalyst Timeline

1 currently tracked

Mar 31, 2027

neffy® (epinephrine nasal spray)

Phase 2b

Company profile

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.